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2 August 2015BACKGROUND AND PURPOSE
Substance P and its preferred neurokinin receptor NK1 have been implicated in stress and anxiety and have been proposed as
possible therapeutic targets for the treatment of anxiety/depression. Attention is also being focused on the role this neuropeptide
system may play in drug addiction, because stress-related mechanisms promote drug abuse.
EXPERIMENTAL APPROACH
The effects of the rat-speciﬁc NK1 receptor antagonist, L822429, on alcohol intake and seeking behaviour was investigated in
genetically selected Marchigian Sardinian alcohol preferring rats. These rats demonstrate an anxious phenotype and are highly
sensitive to stress and stress-induced drinking.
KEY RESULTS
Systemic administration of L822429 signiﬁcantly reduced operant alcohol self-administration in Marchigian Sardinian alcohol
preferring rats, but did not reduce alcohol self-administration in stock Wistar rats. NK1 receptor antagonism also attenuated
yohimbine-induced reinstatement of alcohol seeking at all doses tested but had no effect on cue-induced reinstatement of alcohol
seeking. L822429 reduced operant alcohol self-administration when injected into the lateral cerebroventricles or the medial
amygdala. L822429 injected into the medial amygdala also signiﬁcantly reduced anxiety-like behaviour in the elevated plus maze
test. No effects on alcohol intake were observed following injection of L822429 into the dorsal or the ventral hippocampus.
Conclusions and Implications
Our results suggest that NK1 receptor antagonists may be useful for the treatment of alcohol addiction associated with stress or
comorbid anxiety disorders. The medial amygdala appears to be an important brain site of action of NK1 receptor antagonism.Abbreviations
AP, antero-posterior; CeA, central amygdala; CRF, corticotropin releasing factor; DH, dorsal hippocampus; DV, dorsal-ven-
tral; EPM, elevated plus maze; ML, medial-lateral; msP rats, Marchigian Sardinian (alcohol) preferring rats; SP, substance P;
TO, time out; VH, ventral hippocampus© 2015 The British Pharmacological Society
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Substance P (SP) and its preferred neurokinin NK1 receptor
are involved in stress and anxiety-like behaviour (Santarelli
et al., 2001; McLean, 2005; Ebner and Singewald, 2006; Ebner
et al., 2008). Neuropeptidergic systems involved in stress and
anxiety have frequently attracted the interest of the re-
searchers as targets for the pharmacotherapy of alcoholism
(Ubaldi et al., 2013). SP and NK1 receptors are highly
expressed in areas involved in the modulation of stress, anx-
iety and mood responses, such as the cingulate cortex, cau-
date putamen, nucleus accumbens, septum, hippocampus,
amygdala, dorsal raphe and locus coeruleus (McLean, 2005;
Ebner et al., 2008). Emotional and physical stressors modu-
late SP tissue levels or SP immunoreactivity in brain areas that
are involved in fear and anxiety (Siegel et al., 1987; Nakamura
et al., 1990). Blockade of NK1 receptors has consistently been
shown to exert anxiolytic and anti-depressant effects (see
Mclean, 2005).
The NK1 receptor system may additionally play a role in
excessive alcohol drinking and relapse (see Schank et al.,
2012; Schank, 2014). For instance, systemic administration
of an NK1 receptor antagonist attenuated stress-induced rein-
statement of alcohol seeking in non-selected Wistar rats
(Schank et al., 2011). At the same doses, the NK1 receptor an-
tagonist did not have effects on self-administration of alcohol
under baseline conditions, nor did it affect cue-induced rein-
statement of alcohol seeking or novel environment-induced
locomotion (Schank et al., 2011). This suggests that NK1 re-
ceptors affect alcohol drinking and seeking that are moti-
vated by the need to attenuate stress and anxiety in
vulnerable individuals. To investigate this hypothesis, we
evaluated the effect of NK1 receptor blockade on alcohol-
related behaviours in genetically selected Marchigian Sardin-
ian alcohol preferring (msP) rats.
This strain of msP rats is highly sensitive to stress and
stress-induced excessive alcohol seeking (Ciccocioppo et al.,
2006), show an anxious phenotype (Hansson et al., 2006),
morphological and functional brain alterations, similar to
those in depressed patients (Gozzi et al., 2013), and
depressive-like symptoms that recover following alcohol con-
sumption (Ciccocioppo et al., 1999). ThemsP rats also display
a high alcohol preference and intake, with an excessive daily
alcohol drinking (6–8 g·kg1 body weight) in a binge-type
pattern, leading to signiﬁcant blood alcohol levels
(Ciccocioppo, 2013). Altogether, these data suggest that rats
of this strain may be useful as a model of a sub-populationof alcoholic patients in whom excessive drinking and relapse
vulnerability is associated with co-morbid anxiety and is mo-
tivated by negative reinforcement, or ‘tension relief’
mechanisms.
It is also relevant to note that msP rats have an innate up-
regulation of the corticotropin releasing factor CRF1 receptor
transcript and receptor density (Hansson et al., 2006). This
strain of rats show a reduction in alcohol drinking in re-
sponse to CRF1 receptor antagonists, at doses that have no ef-
fect in non-dependent, non-selected rats (Hansson et al.,
2006), whereas CRF1 receptor gene expression is reduced fol-
lowing voluntary drinking in these animals (Hansson et al.,
2007). There could be some similarity between the actions
of CRF1 receptor antagonists and NK1 receptor antagonists
(Schank et al., 2011). For instance, NK1 receptor antagonists
can reduce alcohol consumption in conditions of high or
escalated intake similar to CRF1 receptor antagonists
(Cippitelli et al., 2012). Furthermore, as with CRF1 receptor
antagonists, NK1 receptor antagonists attenuated stress-
induced reinstatement to alcohol seeking in non-selected
Wistar lines, an effect not observed in the cue-induced
model (Marinelli et al., 2007, Liu and Weiss, 2002, Schank
et al., 2011). It was therefore of great interest to investigate
the effect of NK1 receptor antagonism on alcohol drinking
in the msP strain of rats.
Based on these ﬁndings, we predicted that NK1 receptor
blockade, contrary to what has been observed in heteroge-
neous, non-selected Wistar rats, should reduce drinking in
msP rats and that this effect should occur concomitantly with
an anxiolytic action. To explore this hypothesis, we used
L822429, an NK1 receptor antagonist developed to possess
high afﬁnity for the rat NK1 receptor (Ebner et al., 2004; Ebner
et al., 2008; Singewald et al., 2008; Schank et al., 2011), and
that exhibits anxiolytic properties (Ebner et al., 2004). The ef-
fect of L822429 was assessed on alcohol self-administration
in msP rats and for comparison in Wistar rats. Moreover, in
the msP rats, we evaluated the effect of NK1 receptor blockade
on stress and cue-induced reinstatement of alcohol seeking.
In the attempt to determine the brain sites of action of the
NK1 receptor antagonist on alcohol intake, intracranial ad-
ministrations of L822429 were also carried out in areas rich
in SP ﬁbres and NK1 receptors, which include the hippocam-
pus and medial amygdala (Roberts et al., 1982; Nakaya et al.,
1994; Borhegyi and Leranth, 1997; Ribeiro-da-Silva and
Hokfelt, 2000; Ogier and Raggenbass, 2003). Finally, to link
the reduction of alcohol drinking by the NK1 receptor antag-
onist to its anxiolytic action, we explored the consequencesBritish Journal of Pharmacology (2015) 172 5136–5146 5137
BJP L O Ayanwuyiof injecting L822429 directly into the medial amygdala, on
the results from the elevated plus maze (EPM) test, an
established measure of anxiety in rodents.Methods
Animals
All animal care and experimental procedures followed the EU
directive for Care and Use of Laboratory Animals and were ap-
proved by the Ethical Committee of the University of
Camerino. All studies involving animals are reported in ac-
cordance with the ARRIVE guidelines for reporting experi-
ments involving animals (Kilkenny et al., 2011; McGrath
and Lilley, 2015). A total of 59 animals were used in the exper-
iments described here.
Male msP andWistar rats (Charles River, Calco, Italy) were
used for the study. They were housed two per cage on a reverse
12 h light/dark cycle (lights off at 0900) at a constant temper-
ature of 20 ± 2 °C and relative humidity of 45–55%. Food and
water were available ad libitum. At the time of drug treat-
ments, their body weights ranged between 450 and 550 g.
Animals were handled daily for 1week prior the start of
experimentation.Preparation of drugs used
Alcohol solution (10% v/v) was prepared by diluting 95% al-
cohol (F.L. Carsetti s.n.c., Italy) in tap water. The NK1 receptor
antagonist, L822429 [2-cyclopropoxy-5-(5-(triﬂuoromethyl)
tetrazol-1-yl)ben-zyl]-(2-phenylpiperidin-3-yl)amine, was
synthesized in the laboratory of Dr K. Rice at the NIDA Intra-
mural Research Program. L822429 was dissolved in 45% w/v
2-hydroxypropyl β-cyclodextrin and the pH adjusted. The
compound was injected i.p. in a volume of 1–2mL·kg1. Yo-
himbine (Sigma-Aldrich, Milano, Italy) was dissolved in dis-
tilled water and injected i.p. in a volume of 1mL·kg1.Operant self-administration apparatus and
training
Training and testing were conducted in standard operant
conditioning chambers housed in sound-attenuating cubi-
cles (Med Associates Inc., USA). Each operant chamber was
equipped with a drinking reservoir (volume capacity:
0.3mL) positioned 4 cm above the grid ﬂoor in the centre of
the front panel of the chamber and two retractable levers po-
sitioned laterally (3 cm) to either side of the drinking recepta-
cle. Auditory and visual stimuli were presented via a speaker
located on the front panel and light located on the back panel
respectively. A microcomputer controlled the delivery of the
ﬂuids, presentation of auditory and visual stimuli and record-
ing of the behavioural data. Each response on the active lever
resulted in delivery of 0.1mL of ﬂuid, while responses on the
second lever had no consequences. For 30min·each day, rats
were trained to self-administer 10% (v/v) alcohol solution
on a ﬁxed ratio 1 schedule of reinforcement with a time-out
(TO) of 5 s. The TO period (during which lever responses are
recorded but not reinforced) was signalled by illumination
of a white house light located at the back panel for 5 s.5138 British Journal of Pharmacology (2015) 172 5136–5146Experiments were commenced when a stable baseline of
responding was achieved.
Stereotaxic surgery
The msP rats were anaesthetised by i.m. injection of
250–300 μL of a solution (Zoletil®) containing 58.17mg·mL
tiletamine chlorhydrate and 57.5mg·ml1 zolazepam
chlorhydrate (VIRBAC, Carros, France). Atropine sulphate
(80 μg in 80 μL; Fattro S.P.A., Ozzano Emilia (BO), Italy) was
also administered to the rats. For intracerebroventricular
(i.c.v.) injections, a stainless steel guide cannula (7mm
length) aimed at the lateral ventricle was stereotaxically im-
planted. Taking bregma as reference point, the following co-
ordinates were used: AP = 1.0mm, ML = 1.8mm and DV =
2.0mm. For the dorsal hippocampus (DH), ventral hippo-
campus (VH) and medial amygdala injections, each animal
was stereotaxically implanted with a unilateral guide stain-
less steel cannula (12mm length) in each hemisphere over
the DH, VH orMeA. Taking bregma as reference point, the fol-
lowing coordinates were used: DH: AP = 4.2mm, ML =
2.6mm and DV = 2.9mm; VH: AP = 4.8mm, ML =
5.1mm and DV = 5.0mm; MeA: AP = 2.7mm, ML =
3.4mm and DV= 7.0mm (Paxinos and Watson, 1988). In-
jector lengths used for the injection were 1.5mm longer than
the cannula for DH and VH and 2.0mm longer for MeA. At the
end of the surgery, each guide cannula was sealed with a stain-
less steel wire (0.3mm in diameter), and rats were given a single
i.m. injection (500μL) of rubrocillin (Intervet, Schering-Plough
Animal Health, Segrate (MI), Italy) as a prophylactic antibiotic.
Rats were allowed to recover from surgery for 1week during
which they were monitored daily for signs of pain or distress.
Correct cannula placement of the ICV guide cannulae was con-
ﬁrmed with angiotensin II (Gosnell et al., 1990; Choi et al.,
2003) (Supporting Information).
At completion of the experiment, the animals were killed
by CO2 inhalation and then the brains were quickly removed
and snap-frozen at 20°C in isopentane. The brains were
then stored at 80°C. The correct placement of the cannulae
was further veriﬁed by histological examination (Supporting
Information). Only behavioural data obtained from rats that
had the cannulae correctly placed in both hemispheres of
the brain were analysed (N = 7 for DH, N = 9 for VH, N = 8
and N = 14 for MeA, self-administration and EPM experi-
ments, respectively).Effect of L822429 on alcohol and saccharin
self-administration
One group ofmsP rats (N = 7) and another of non-selectedWistar
rats (N = 10) were trained to self-administer 10% (v/v) alcohol so-
lution as described previously. In a within-subject Latin square
counterbalanced order, 1h before the beginning of the session,
rats were treated with different doses of L822429 (0, 5, 15 and
30mg·kg1) i.p. Drug treatment was performed every fourth
day. Thus, four rounds of drug treatment were performed, with
each rat receiving all four doses of L822429. The ﬁrst day after
drug test, rats remained in their home cage, whereas on days 2
and 3, the baseline alcohol self-administrationwas re-established.
Under identical experimental conditions, the study was repli-
cated in another group ofmsP rats (N = 7) with saccharin solution
(0.2%) as the reinforcer.
NK1 antagonism and alcohol drinking and relapse BJPEffect of L822429 on yohimbine-induced
reinstatement of alcohol seeking in msP rats
A group of msP rats (N = 9) were trained to self-administer
10% (v/v) alcohol solution as described previously. The rats
were then subjected to 30min extinction sessions for 16 con-
secutive days. Sessions were identical to those of the self-
administration training, with the exception that lever re-
sponses were not associated with alcohol delivery. Following
the extinction phase, the rats were treated i.p. with L822429
(0, 5, 15 and 30mg·kg1) according to a counterbalanced
Latin square (within-subject) design 1 h before the reinstate-
ment session. Yohimbine (1.25mg·kg1) was given i.p. to all
the rats 30min after the L822429 administration. A 4-day in-
terval, during which animals were subjected to extinction
sessions, was allowed between drug tests (Cippitelli et al.,
2008). Thus, four rounds of drug treatment were performed,
with each rat receiving all four doses of L822429.
Effect of L822429 on cue-induced
reinstatement of alcohol seeking in msP rats
These msP rats (N = 9) were trained to discriminate between
10% alcohol and water in 30min daily sessions. The discrim-
inative stimulus for alcohol was the odour of an orange ex-
tract (S+), whereas water availability was signalled by an
anise extract (S). In addition, each lever press resulting in al-
cohol delivery was paired with illumination of the chamber’s
house light for 5 s. The corresponding cue during water ses-
sions was a 5 s tone (70 dB). Concurrently with the presenta-
tion of these stimuli, a 5 s TO period was in effect during
which responses were recorded but not reinforced. Following
the conditioning phase, rats were subjected to 30min extinc-
tion sessions for six consecutive days. During this phase, ses-
sions began by extension of the levers without presentation
of the discriminative stimuli, associated delivery of liquids
or response-contingent cues. After the extinction phase, rein-
statement tests began under conditions identical to those
during the conditioning phase, except that alcohol and water
were not made available. The msP rats were tested under the
S condition on day 1. On day 2, the rats were treated i.p.
with L822429 (0, 5, 15 and 30mg·kg1) 1 h before the begin-
ning of the reinstatement test under the S+ condition accord-
ing to a counterbalanced Latin square (within-subject)
design. A 4-day interval, during which animals remained in
their home cage, was allowed between drug tests
(Ciccocioppo et al., 2002; Cippitelli et al., 2008). Thus, four
rounds of drug treatment were performed, with each rat re-
ceiving all four doses of L822429.
Effect of L822429 administered intracranially
on alcohol self-administration in msP rats
A group of msP rats (N = 8) was trained to self-administer 10%
(v/v) alcohol solution as described previously. The rats then
underwent surgery to implant a cannula into the lateral
cerebroventricle and, after recovery, were subjected to alcohol
self-administration again. Following acquisition of a stable
baseline of alcohol self-administration, L822429 treatment
began. In a within-subject Latin square counterbalanced de-
sign, rats were treated with L822429 (30 μg in·2 μL per rat)
or its vehicle 10min before the beginning of the session.
Drug treatment was performed every third day. The ﬁrst dayafter drug test, rats remained in their home cage, whereas
on day 2, the baseline alcohol self-administration was re-
established. This experiment was also performed using lower
doses (0, 7.5 and 15 μg·μl1 per rat) of the NK1 receptor antag-
onist (see Supporting Information for results).
In a similar experiment, three groups of msP rats (N = 7–9 per
group) trained to self-administer 10% (v/v) alcohol were im-
planted bilaterally with cannulae into the DH, VH and medial
amygdala respectively. The doses of L822429 evaluated here were
0, 7.5 and15μgper rat (0.3μLper side). Treatmentwas carried out
in a within-subject Latin square counterbalanced design.Effect of injection of L822429 into medial
amygdala on anxiety-like behaviour in msP
rats
To measure anxiety-like responses, the elevated plus maze
(EPM) test was used. The maze, elevated 50 cm above the
ﬂoor, was located in a sound attenuated room illuminated
by a red dim light (~30 lx). Two groups of rats (N = 7 per group)
were injected with L822429 (15 μg per rat; 0.3 μL per side) or
its vehicle into the MeA. Ten minutes later, animals were
tested in the EPM arena. The 5min test procedure began
when the animals were individually placed in the centre of
the maze, facing a closed arm. A rat was considered to be on
the central platform when at least two of its paws were on
it. An entry was deﬁned as the presence of all four paws in
the arms. The percent of time spent in the open arm, the
number of open arm entries and the number of total arm en-
tries were recorded by an automated videotracking system
(Noldus Ethovision XT 7.0). Data were then analysed by an
experimenter unaware of the experimental treatments.Data analysis
Self-administration, reinstatement and intracranial experi-
ments were evaluated by one-way ANOVA with repeated
measures using drug dose as a within-subject factor. Ana-
lysis of variance was followed by the Newman–Keuls test
when found to be signiﬁcant. Statistical signiﬁcance was
set at P < 0.05. Data obtained from the EPM experiment
were analysed using Student’s t-test. Statistical signiﬁcance
was set at P < 0.05. Statistica version 8 (StatSoft, Inc. Tulsa,
OK, USA) was used for statistical analysis of the data.Results
L822429 reduces alcohol self-administration
in msP but not Wistar rats
Rats rapidly acquired stable alcohol self-administration. As
shown in Figure 1A, treatment with L822429 signiﬁcantly re-
duced operant responding for alcohol in msP rats [F(3,6) = 24.5;
P < 0.001]. Post hoc analysis revealed a signiﬁcant reduction of
alcohol self-administration at the doses of 5mg·kg1 (P < 0.01),
15mg·kg1 (P< 0.01) and30mg·kg1 (P< 0.001), demonstrating
a dose-dependent effect. There was no signiﬁcant effect of
L822429 treatment on alcohol self-administration in Wistar
rats (Figure 1B). ANOVA did not show any signiﬁcant main
effect of treatment [F(3,9)=1.34, NS]. In msP rats, L822429British Journal of Pharmacology (2015) 172 5136–5146 5139
Figure 1
Effect of L822429 (0, 5, 15 and 30mg·kg1) on alcohol self-adminis-
tration in msP (A) and Wistar (B) rats under ﬁxed ratio 1 schedule of
reinforcement. Panel A shows that alcohol self-administration is
dose-dependently reduced by L822429 in msP rats (N = 7). Panel B
shows that there is no signiﬁcant effect of L822429 treatment on
alcohol self-administration in Wistar rats (N = 10). Data are the mean
(±SEM) number of rewards in 30min. L822429 was given i.p.
***P< 0.001; **P< 0.01; *P< 0.05, signiﬁcant differences from vehi-
cle-treated (0mg·kg1) rats.
Figure 2
Effect of L822429 (5, 10, 15 and 30mg·kg1) on operant saccharin
self-administration in msP rats under ﬁxed ratio 1 schedule of rein-
forcement. Data are the mean ±SEM of total number of rewards
earned in 30min. L822429 was given i.p. No signiﬁcant differences
were found between vehicle-treated (0mg·kg1) and drug treated
groups (N = 7).
BJP L O Ayanwuyidid not signiﬁcantly modify operant responding for saccharin
[[F(3,6)=0.07, NS] (Figure 2)].
In the experiments, responses at the inactive lever were
extremely low and were not affected by L822429 treatment
(data not shown).L822429 attenuates yohimbine-induced
reinstatement of alcohol seeking in msP rats
After a stable baseline of responding to 10% alcohol was
established during the self-administration phase (mean ±
SEM of the last 3 days: 52 ± 4.6), extinction was initiated
and the responses to alcohol progressively decreased. As5140 British Journal of Pharmacology (2015) 172 5136–5146shown in Figure 3A, administration of yohimbine
(1.25mg·kg1) signiﬁcantly reinstated the operant
responding for alcohol [F(1,8) = 9.75, P < 0.05]. ANOVA
showed that pre-treatment with L822429 signiﬁcantly re-
duced the effect of yohimbine [F(3,8) = 4.25, P < 0.05]. Post
hoc analysis revealed a signiﬁcant dose-related inhibition of
reinstatement following administration of the NK1 receptor
antagonist (5, 15 and 30mg·kg1). Statistical analysis of the
inactive lever responses showed that there was no effect of
yohimbine treatment, indicating its selectivity to elicit rein-
statement of alcohol seeking (data not shown).L822429 does not affect cue-induced
reinstatement of alcohol seeking in msP rats
ANOVA showed a signiﬁcant overall effect of conditioning
[F(1,16)= 27.82, P < 0.001] during the discrimination phase.
Animals responded at a signiﬁcantly higher level for alcohol
(mean ± SEM of the last 3 days for alcohol: 53 ± 4.5) than
for water (mean ± SEM of the last 3 days for water: 14 ± 2.1).
During extinction, lever pressing progressively decreased.
In the reinstatement test, ANOVA showed that cues had a
signiﬁcant overall effect on alcohol seeking [F(2,8) = 11.46;
P < 0.001]. A more detailed analysis showed a robust rein-
statement of responding under the S+ (P < 0.01) but not un-
der the S (P > 0.05, NS) compared with the last day of
extinction. As shown in Figure 3B, pre-treatment with
L822429 did not affect conditioned reinstatement of alcohol
seeking [F(3,8) = 16.59; NS]. Responses at the inactive lever
were not inﬂuenced by the treatment.Intracerebroventricular administration of
L822429 reduces alcohol self-administration
in msP rats
ANOVA revealed a signiﬁcant effect of the treatment [F(1,7) = 24.0,
P ≤ 0.01] on alcohol self-administration. As shown in Figure 4, the
i.c.v administration of L822429 at the dose of 30μg per rat signif-
icantly reduced alcohol self-administration in the msP rats. Inac-
tive lever responses were not inﬂuenced by the L822429
Figure 3
Effect of L822429 (0, 5, 15 and 30mg·kg1) on (A) yohimbine-induced reinstatement of alcohol seeking and (B) cue-induced reinstatement of
alcohol seeking. S, S+ refer to the discriminative stimuli indicating water and alcohol availability respectively. Data are the mean (±SEM) number
of responses on the active lever in 30min (N = 9 for each experiment). L822429 was administered via the intraperitoneal route. **P< 0.01;
*P< 0.05, signiﬁcant differences from vehicle-treated group (0mg·kg1). # P< 0.01, signiﬁcant difference from extinction. Data from the last
day of extinction with water-paired cues are shown as S-/CS-; the alcohol-paired cues are shown as S+/CS+.
Figure 4
Effect of i.c.v. injection of L822429 (0.0, 30.0 μg per rat) on alcohol
self-administration in msP rats under ﬁxed ratio 1 schedule of rein-
forcement. Data are the mean ± SEM of number of rewards earned
in 30min (N = 8). **P< 0.01, signiﬁcant difference from vehicle-
treated group (0 μg per rat).
NK1 antagonism and alcohol drinking and relapse BJPtreatment. No appreciable effect of L822429 was found at the
lower doses of 7.5 and 15μg per rat (Figure S2).L822429 attenuates alcohol
self-administration in msP rats when
administered into the medial amygdala but not
the dorsal hippocampus or ventral
hippocampus
ANOVA showed that the administration of L822429 into the
dorsal hippocampus (Figure 5A) did not signiﬁcantly modify
alcohol self-administration [F(2,6) = 2.23, NS]. As shown in
Figure 5B, there was also no signiﬁcant effect of L822429 ad-
ministration into the ventral hippocampus [F(2,8) = 0.26,
NS]. However, there was a signiﬁcant reduction of alcohol
self-administration when the drug was injected into the me-
dial amygdala [F(2,7) = 6.3, P < 0.05]. As shown in Figure 5C,British Journal of Pharmacology (2015) 172 5136–5146 5141
Figure 5
Effect of L822429 injection (0, 7.5 and 15 μg per rat) into the dorsal
hippocampus (A), ventral hippocampus (B) and medial amygdala
(C) on alcohol self-administration in msP rats under ﬁxed ratio 1
schedule of reinforcement. Data are the mean ± SEM of total number
of rewards earned in 30min (N = 7–9 per group). *P< 0.05, signiﬁ-
cant difference from vehicle-treated group (0mg·kg1).
Figure 6
Effect of L822429 injection (0, 15 μg per rat) into the medial amyg-
dala on the time spent on the open arms (A), the percentage of en-
tries into the open arms (B) and the total number of entries (C) in
the elevated plus maze test. Data are expressed as the mean ±SEM
(N = 7 per group). ***P< 0.001, signiﬁcant difference from vehicle-
treated group.
BJP L O Ayanwuyipost hoc analysis revealed that alcohol self-administration was
signiﬁcantly reduced at the dose of 15 μg per rat.Micro-injection of L822429 into the medial
amygdala attenuates anxiety-like behaviour of
msP rats in elevated plus maze test
As shown in Figure 6, L822429 treatment (15 μg per rat) sig-
niﬁcantly increased the percentage of time spent in the open
arms [t(12) = 5.69, P < 0.0001] and the percentage of open
arm entries [t(12) = 4.97, P < 0.0001]. Conversely, drug5142 British Journal of Pharmacology (2015) 172 5136–5146exposure reduced the total number of closed arm entries
[t(12) = 4.97, P < 0.0001]. Total arm entries were not affected
by treatment [t(12) = 1.19, P > 0.05].Discussion
In agreement with previous reports (Schank et al., 2011;
Schank et al., 2013), we found that the NK1 receptor antago-
nist L822429 did not modify basal alcohol self-
administration in non-selected Wistar rats. In contrast, in ge-
netically selected msP rats, L822429 did attenuate alcohol
self-administration at doses that did not modify saccharin-
reinforced operant responding. This indicates that the action
of the NK1 receptor antagonist is selective for alcohol in msP
rats, consistent with previous ﬁndings with another selected
line, the alcohol preferring (P) rat (Schank et al., 2013). Fur-
thermore, and also in agreement with previous work (Schank
et al., 2011; Schank et al., 2014), NK1 receptor blockade sup-
pressed reinstatement of alcohol seeking elicited by the phar-
macological stressor yohimbine, but not by cues previously
NK1 antagonism and alcohol drinking and relapse BJPassociated with alcohol availability. We also conﬁrmed that
L82242 exerted its effects via central mechanisms and that
the medial amygdala is an important site of action for the
NK1 receptor antagonist on alcohol intake in msP rats. Fi-
nally, we demonstrated that the injection of L822429 into
the medial amygdala of msP rats decreased anxiety-like be-
haviour in the EPM test under baseline conditions, suggest-
ing that the reduction of alcohol intake elicited by the NK1
receptor antagonist may be driven by inhibition of innate
anxiety and negative emotionality in these rats.
The NK1 receptor mediates anxiety and stress (McLean,
2005; Ebner and Singewald, 2006), and it is known that these
negative emotional states promote the compulsivity of alco-
hol drinking (Koob and Le Moal, 2006). Also, NK1 receptor
antagonists are effective in the reduction of anxiety, depres-
sion and stress-related states (Ebner and Singewald, 2006).
Our ﬁndings therefore suggest that the likely mechanism by
which the NK1 receptor antagonist was able to reduce alcohol
drinking was by attenuating these negative emotional states
that drive drinking behaviour in vulnerable individuals. This
may explain why NK1 receptor antagonists reduced alcohol
self-administration in the msP rats, which are postulated to
drink to alleviate an innate high anxiety state, but not in
their Wistar counterparts. This is in agreement with the study
by Schank et al. (2011) that showed no effects of the NK1 re-
ceptor antagonist on alcohol drinking in non-selected Wistar
rats (Schank et al., 2011). To our knowledge in fact, only one
study has reported inhibition of alcohol drinking in hetero-
geneous rats following NK1 receptor antagonism, but the ef-
fect was observed at doses that also suppressed sucrose
consumption (Steensland et al., 2010). This indicates that
high doses of a NK1 receptor antagonist could elicit a general
inhibitory effect on appetitive behaviour.
Interestingly, inhibition of the NK1 receptor by pharma-
cological antagonism or genetic deletion reduced alcohol in-
take in mice of the C57/BL6 strain (George et al., 2008;
Thorsell et al., 2010), which have relatively high alcohol pref-
erence (Belknap et al., 1993). This would be compatible with
our observations in alcohol preferring rat strains and suggests
that NK1 receptor antagonists can reduce alcohol consump-
tion in conditions of high or escalated intake similar to
CRF1 receptor antagonists (Cippitelli et al., 2012).
The NK1 receptor antagonist attenuated stress-induced re-
instatement to alcohol seeking in this study. The stressor
employed was yohimbine, an α2-adrenoceptor antagonist
that increases noradrenergic cell ﬁring (Aghajanian and
VanderMaelen, 1982) and enhances noradrenaline release in
terminal areas (Abercrombie et al., 1988; Pacak et al., 1992).
Yohimbine induces anxiety-like responses in both humans
(Holmberg and Gershon, 1961; Bremner et al., 1996b) and
laboratory animals (Bremner et al., 1996a) and triggers
craving in alcohol-dependent patients (Umhau et al., 2011).
The ability of the NK1 receptor antagonist to attenuate
stress-induced reinstatement to alcohol seeking suggests the
possible involvement of the SP/NK1 receptor system in
stress-induced craving in alcohol dependence. Indeed, a re-
cent clinical trial using an NK1 receptor antagonist found
beneﬁcial effects on baseline and stress-elicited alcohol
craving (George et al., 2008). The ability of the NK1 receptor
antagonist to attenuate stress-induced reinstatement to alco-
hol seeking and not affect cue-induced reinstatement toalcohol seeking parallels the study of Schank and colleagues,
where similar effects were observed in non-selected Wistar
rats (Schank et al., 2011). This further supports the notion
that stress may be a necessary precondition for NK1 receptor
antagonists to elicit their alcohol-seeking suppressing effects.
These ﬁndings also underscore another important similarity
between the antagonists of SP/NK1 receptor and CRF/CRF1 re-
ceptor systems in the modulation of alcohol intake. CRF1 re-
ceptor antagonists suppress stress-induced reinstatement to
alcohol seeking in msP lines (Hansson et al., 2006) and non-
selected Wistar lines (Marinelli et al., 2007) while being inef-
fective on cue-reinstatement models (Liu and Weiss, 2002).
It is tempting to speculate that both the SP/NK1 receptor
and the CRF/CRF1 receptor systems might share common
neurobiological pathways. For instance, like CRF, SP and the
NK1 receptor might be involved in the neuroadaptations in-
duced by history of alcohol dependence or escalated intake.
To support this hypothesis, NK1 receptor knock-out mice
failed to escalate their alcohol consumption after repeated cy-
cles of deprivation (Thorsell et al., 2010), suggesting that the
SP/NK1 receptor system may mediate neuroadaptive changes
that contribute to the escalation of alcohol intake, a hallmark
of addiction.
The ability of the NK1 receptor antagonist to reduce alco-
hol drinking in the up-regulated CRF state of msP rats sug-
gests that there could be an interaction between the actions
of SP and CRF in the brain. In a study that investigated the
differential gene expression proﬁle induced by SP in human
astronoma and rat astroglial cells using microarray tech-
niques, SP was shown to induce the expression of CRF1 recep-
tors, an effect that was inhibited by a selective NK1 receptor
antagonist (Hamke et al., 2006). In addition, SP has also been
shown to increase CRF1 receptor mRNA and induce the ex-
pression of the CRF1 receptor protein in human mast cells
(Asadi et al., 2012). This indicates that SP could induce CRF1
receptor expression in brain regions that mediate anxiety
and stress-induced alcohol intake. Taken together, these data
suggest that a cross-talk may exist between the two neuropep-
tide systems in the modulation of stress-induced drinking in
msP rats. However, there is a possibility that NK1 receptor
and CRF1 receptor systems use parallel pathways to mediate
stress-induced behaviours, or that these systems converge
on a common downstream target. Future research should fo-
cus on exploring these possibilities.
The hippocampus is a brain structure involved in many
functional processes such as learning and memory as well as
regulation of emotions (Eichenbaum, 2000; Engin and Treit,
2007) and has a high density of SP-containing ﬁbres, which
derive from intrinsic and extrinsic origins (Borhegyi and
Leranth, 1997). In the hippocampus, SP effects are mediated
by NK1 receptors (Ogier and Raggenbass, 2003) even though
other neurokinin receptor subtypes are present in this brain
structure (Maeno et al., 1993; Quartara and Maggi, 1998).
Thus, we were interested in studying the effect of NK1 recep-
tor antagonism in this brain area on alcohol intake. Our re-
sults showed that neither NK1 receptor antagonism in the
dorsal nor the ventral hippocampus inﬂuenced alcohol in-
take in msP rats. The hippocampus is known to play a role
in drug reinforcement, craving and cue-induced relapse
(Volkow, 2004; Martin-Fardon et al., 2008; Koob and Volkow,
2010b), whereas not much is known about its role in theBritish Journal of Pharmacology (2015) 172 5136–5146 5143
BJP L O Ayanwuyimodulation of negative states associated with addiction.
Based on present ﬁndings, we would speculate that the NK1
receptor system located in this brain structure was not in-
volved in the modulation of drinking behaviour, nor did it
contribute to the regulation of negative affect associated with
the innate high alcohol vulnerability of msP rats.
On the other hand, a suppression of alcohol intake was
observed when the drug was injected into the MeA. Notably,
the effect in the medial amygdala was obtained at a dose of
L822429, which was ineffective following i.c.v. administra-
tion. This provides strong evidence for a speciﬁc role of this
area inmediating the effect of NK1 receptor antagonists on al-
cohol drinking. The amygdala is a critical brain structure for
the processing of emotions including fear and anxiety
(Aggleton, 1993; LeDoux, 2003) and has been shown to play
an important role in negative reinforcement that drives com-
pulsive drug use (Koob and Zorrilla, 2010a). SP-containing
neurons as well as NK1 receptors are highly expressed in this
area (Roberts et al., 1982; Nakaya et al., 1994; Ribeiro-da-Silva
and Hokfelt, 2000). The medial amygdala is reported to con-
tain the highest amounts of SP within the amygdala (Roberts
et al., 1982) and immunohistochemical studies have demon-
strated a dense plexus of SP-containing cell bodies and termi-
nals in this area (Ribeiro-da-Silva and Hokfelt, 2000;
Cippitelli et al., 2012). One study showed that within the
amygdala, the medial amygdala is particularly activated by
emotional stress more strongly than the central amygdala,
as indicated by c-fos expression (Dayas et al., 1999). Another
study demonstrated an immobilization stress-induced in-
crease of SP release in themedial amygdala but not in the cen-
tral amygdala (Ebner et al., 2004). Thus, we considered it
relevant to investigate the effect of NK1 receptor antagonism
in this brain area on anxiety in msP rats.
Results from the EPM conﬁrmed that the administration
of L822429 suppressed anxiety-like responses when micro-
injected into the medial amygdala. This agrees with the study
of Ebner et al (2004), which showed that injections of the
same NK1 receptor antagonist into the medial amygdala
blocked anxiogenic-like effects in previously stressed (immo-
bilization stress) rats, as tested with the EPM (Ebner et al.,
2004). Additionally, Ebner and colleagues found that the
NK1 receptor antagonist did not elicit an anxiolytic effect in
unstressed rats but reversed the anxiogenic effect of SP
microinjected into the medial amygdala (Ebner et al., 2004).
Extrapolating these ﬁndings to our study, it could be that
the msP rats have an innately overfunctioning SP system in
the medial amygdala, which may contribute to the typical
negative affective state of these animals, in turn facilitating
their excessive alcohol consumption. Additionally, because
it has also been shown that NK1 receptor activation by SP in-
creases CRF1 receptor expression, it is tempting to speculate
that up-regulation of the extrahypothalamic corticotropin
system described in msP rats may result (Hansson et al.,
2006; Hansson et al., 2007), at least in part, from over-activity
of the neurokinin system. Together, these data indicate an im-
portant role for the SP/NK1 receptor system in the medial
amygdala for the modulation of anxiety and stress-induced
excessive alcohol drinking and seeking. However, recent
studies in P alcohol preferring rats have identiﬁed the central
amygdala as themajor site of NK1 receptor antagonist activity
on excessive alcohol intake in that particular strain (Schank5144 British Journal of Pharmacology (2015) 172 5136–5146et al., 2013). The underlying mechanism of this divergence
is not clear, but it is important to note that these two alcohol
preferring lines were independently generated through
genetic selection under somewhat different selection
conditions.
In conclusion, the ﬁndings in this study demonstrate that
the SP/NK1 receptor system plays an important role in exces-
sive alcohol intake mediated by stress. Like CRF1 receptor an-
tagonists, NK1 receptor antagonists reduce alcohol drinking
in a similar fashion and could represent a viable pharmaco-
logical target for the treatment of alcoholism associated with
stress or co-morbid anxiety disorders. The medial amygdala is
a probable site of action for the effect of the NK1 receptor an-
tagonist on alcohol intake in genetically selected msP rats.Acknowledgements
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Figure S1 Effect of intracerebroventricular injectionof L822429
(0.0, 7.5, 15.0 μg/rat) on alcohol self-administration in msP rats
under FR-1 schedule of reinforcement. Data are the mean ±
SEM of total number of rewards earned in 30min (N=8).
L822429 did not reduce the number of rewards at these doses.
No signiﬁcant differences were found between the treatment
groups. Vehicle-treated group: white bar; drug-treated groups:
black bars.
Figure S2 Microinjections into the Medial Amygdala were
performed within the highlighted area. Taking bregma as
reference point, the following coordinates were used in
accordance with the atlas of Paxinos and Watson, 1998:
Antero-Posterior = 2.7mm; Medio-Lateral = 3.4mm; Dorso-
Ventral = 9.0mm.
